Effects of solvents and crystallization conditions on the polymorphic behaviors and dissolution rates of valsartan

Archives of Pharmacal Research

Volumn 35, Issue 7, 2012, Pages 1223-1230

  Tran, Thao Truong Dinh ^a,b   Tran, Phuong Ha Lien ^a,b   Park, Jun Bom ^b   Lee, Beom Jin ^b,c  

^a INTERNATIONAL UNIVERSITY   (Viet Nam)

^b Kangwon National University   (South Korea)

^c Ajou University   (South Korea)

Author keywords

Crystallization condition; Dissolution rate; Polymorphism; Solvent type; Structural behavior; Valsartan

Indexed keywords

ACETONE; ACETONITRILE; ALCOHOL; VALSARTAN;

ARTICLE; CHINA; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; HEATING; INDIA; MORPHOLOGY; POWDER; POWDER X RAY DIFFRACTION; SCANNING ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ACETONE; ACETONITRILES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; ETHANOL; HOT TEMPERATURE; KINETICS; MICROSCOPY, ELECTRON, SCANNING; POWDER DIFFRACTION; POWDERS; SOLUBILITY; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL; TETRAZOLES; VALINE; WATER;

EID: 84864945960     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0713-7     Document Type: Article

References (28)

1. Adhiyaman, R. and Basu, S. K., Crystal modification of dipyridamole using different solvents and crystallization conditions. Int. J. Pharm., 321, 27-34 (2006). (Pubitemid 44247417)
2. Barone, C. R., Maresca, L., Natile, G., and Pacifico, C., A new polymorph of dichlorido (1,10-phenanthroline)platinum (II). Inorganica Chim. Acta, 366, 384-387 (2011).
3. Cappello, B., Maio, C. D., Iervolino, M., and Miro, A., Improvement of solubility and stability of Valsartan by hydroxypropylboldbeta-Cyclodextrin. J. Incl. Phenom. Macrocycl. Chem., 54, 289-294 (2006). (Pubitemid 43699981)
4. Femi-Oyewo, M. N. and Spring, M. S., Studies on paracetamol crystals produced by growth in aqueous solutions. Int. J. Pharm., 112, 17-28 (1994). (Pubitemid 24292909)
5. Horst, J. H. T., Geertman, R. M., and Rosmalen, G. M. V., The effect of solvent on crystal morphology. J. Cryst. Growth, 230, 277-284 (2001). (Pubitemid 32663719)
6. Hu, J., Johnston, K. P., and Williams, R. O., 3rd., Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur. J. Pharm. Sci., 20, 295-303 (2003). (Pubitemid 37338535)
7. Iqbal, M., Khuroo, A., Batolar, L. S., Tandon, M., Monif, T., and Sharma, P. L., Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Clin. Ther., 32, 588-596 (2010).
8. Krishnaiah, Ch., Reddy, A. R., Kumar, R., and Mukkanti, K., Stability-indicating UPLC method for determination of Valsartan and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. J. Pharm. Biomed. Anal., 53, 483-489 (2010).
9. Kitamura, M. and Ishizu, T., Kinetic effect of L-phenylalanine on growth processof L-glutamic acid polymorph. J. Crystal Growth, 192, 225-235 (1998). (Pubitemid 128415732)
10. Kumar, K. V., Arunkumar, N., Verma, P. R. P., and Rani, C., Preparation and in vitro characterization of valsartan solid dispersions using skimmed milk powder as carrier. Int. J. Pharm. Tech. Res., 1, 431-438 (2009).
11. Li, W.-J., Shi, E.-W., Zhong, W.-Z., and Yin, Z.-W., Growth mechanism and growth habit of oxide crystals. J. Crystal Growth, 203, 186-196 (1999).
12. Mandal, S., Saha, R., Mahanti, B., Fleck, M., and Bandyopadhyay, D., Synthesis, characterization and pseudopolymorphism of a phenoxo-bridged binuclear manganese (III) Schiff base complex. Inorganica Chim. Acta, 387, 1-7 (2012).
13. Megarry, A. J., Booth, J., and Burley, J., Amorphous trehalose dihydrate by cryogenic milling. Carbohydr. Res., 346, 1061-1064 (2011).
14. Näther, C., Jeß, I., Havlas, Z., Bolte, M., Nagel, N., and Nick, S., Trimorphism of 4,4-Di(tert.-butyl)-biphenyl: structural, thermodynamic and kinetic aspects. Solid State Sci., 4, 859-871 (2002).
15. Nokhodchi, A., Bolourtchian, N., and Dinarvand, R., Crystal modification of phenytoin using different solvents and crystallization conditions. Int. J. Pharm., 250, 85-97 (2003). (Pubitemid 35447939)
16. Park, Y. J., Lee, H. K., Im, Y. B., Lee, W., and Han, H. K., Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion. Arch. Pharm. Res., 33, 1235-1240 (2010).
17. Pilcer, G., Wauthoz, N., and Amighi, K., Lactose characteristics and the generation of the aerosol. Adv. Drug Deliv. Rev., 64, 233-256 (2012).
18. Remko, M., Bojarska, J., Jezko, P., Sieroń, L., Olczak, A., and Maniukiewicz, W., Crystal and molecular structure of perindopril erbumine salt. J. Mol. Struct., 997, 103-109 (2011).
19. Shan, G., Igarashi, K., Noda, H., and Ooshima, H., Control of solvent-mediated transformation of crystal polymorphs using a newly developed batch crystallizer (WWDJ-crystallizer). Chem. Eng. J., 85, 169-176 (2002). (Pubitemid 34191307)
20. Shekunov, B. Y. and York, P., Crystallization processes in pharmaceutical technologyand drug delivery design. J. Crystal Growth, 211, 122-136 (2000). (Pubitemid 30583697)
21. Singhal, D. and Curatolo, W., Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. Rev., 56, 335-347 (2004). (Pubitemid 38201429)
22. Suitchmezian, V., Jess, I., and Näther, C., Investigations on the polymorphism and pseudopolymorphism of triamcinolone diacetate. Int. J. Pharm., 323, 101-109 (2006). (Pubitemid 44397369)
23. Tapas, A. R., Kawtikwar, P. S., and Sakarkar, D. M., Spherically agglomerated solid dispersions of valsartan to improve solubility, dissolution rate and micromeritic properties. Int. J. Drug Deliv., 2, 304-313 (2010).
24. Tran, T. T., Tran, P. H., and Lee, B. J., Dissolution-modulating mechanism of alkalizers and polymers in a nanoemulsifying solid dispersion containing ionizable and poorly water-soluble drug. Eur. J. Pharm. Biopharm., 72, 83-90 (2009).
25. Tran, T. T., Tran, P. H., Choi, H. G., Han, H. K., and Lee, B. J., The roles of acidifiers in solid dispersions and physical mixtures. Int. J. Pharm., 384, 60-66 (2010).
26. Uchimoto, T., Iwao, Y., Takahashi, K., Tanaka, S., Agata, Y., Iwamura, T., Miyagishima, A., and Itai, S., A comparative study of glycerin fatty acid ester and magnesium stearate on the dissolution of acetaminophen tablets using the analysis of available surface area. Eur. J. Pharm. Biopharm., 78, 492-498 (2011).
27. Widjaja, E., Kanaujia, P., Lau, G., Ng, W. K., Garland, M., Saal, C., Hanefeld, A., Fischbach, M., Maio, M., and Tan, R. B., Detection of trace crystallinity in an amorphous system using Raman microscopy and chemometric analysis. Eur. J. Pharm. Sci., 42, 45-54 (2011).
28. Youn, Y.-S., Oh, J. H., Ahn, K. H., Kim, M., Kim, J., and Lee, Y.-W., Dissolution rate improvement of valsartan by low temperature recrystallization in compressed CO2: Prevention of excessive agglomeration. J. Supercrit. Fluids, 59, 117-123 (2011).